SAN DIEGO, March 12, 2019 — Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell ision (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today that it has regained compliance with Nasdaq listing requirements. In a letter dated March 11, 2019, Nasdaq informed the Company that it has regained compliance with the minimum bid price requirement.
About Trovagene, Inc.
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision medicine approach to develop drugs that target mitosis (cell ision) to treat various types of cancer, including leukemias, lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics. For more information, please visit https://www.trovageneoncology.com.
VP, Clinical Development
SOURCE Trovagene, Inc.